Showing results (101-110 of 218) with videos related to
Sort By:
Pageof 22
Journal for Immunotherapy of Cancer|June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancerMiguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.Cancer Discovery|August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint BlockadeQu Zhang, Jia Luo, Song Wu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.Pageof 22